ReShape Lifesciences Inc. (RSLS)
| Market Cap | 33.52M |
| Revenue (ttm) | 12.14M |
| Net Income (ttm) | -38.15M |
| Shares Out | 6.97M |
| EPS (ttm) | -5.65 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 23 |
| Last Price | $6.50 |
| Previous Close | $7.29 |
| Change ($) | -0.79 |
| Change (%) | -10.84% |
| Day's Open | 7.00 |
| Day's Range | 6.50 - 7.15 |
| Day's Volume | 3,117 |
| 52-Week Range | 1.51 - 11.5 |
ReShape Lifesciences' (RSLS) CEO Bart Bandy on Q3 2019 Results - Earnings Call Transcript
ReShape Lifesciences Inc. (RSLS) CEO Bart Bandy on Q2 2019 Results - Earnings Call Transcript
ReShape Lifesciences Inc. (RSLS) CEO Bart Bandy on Q1 2019 Results - Earnings Call Transcript
ReShape Lifesciences Inc.'s (RSLS) CEO Dan Gladney on Q4 2018 Results - Earnings Call Transcript
About RSLS
ReShape Lifesciences, a medical device company, focuses on the design, development, and commercialization of technology to treat obesity and metabolic diseases. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in morbidly obe... [Read more...]
| Industry Medical Devices | IPO Date Nov 15, 2007 |
| CEO Barton Bandy | Employees 38 |
| Stock Exchange OTCMKTS | Ticker Symbol RSLS |
Financial Performance
In 2019, RSLS's revenue was $15.09 million, an increase of 2,385.83% compared to the previous year's $607,000. Losses were -$74.21 million, -8.56% less than in 2018.